TNFRSF13C and B-cell chronic lymphocytic leukemia: Antibodies targeting BAFF-R were demonstrated to promote NK cell-mediated killing of B-ALL, CLL and MCL cells in pre-clinical studies [213,218,219], and currently, anti-BAFF-R antibody ianalumab (VAY736) is being evaluated in the treatment of CLL patients in combination with ibrutinib (NCT03400176).